References
- Substance Abuse and Mental Health Services Administration. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. NSDUH Series H-48, HHS Publication No. (SMA) 14–4863.
- Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs?. Addict Behav. 2014;39:1430–1433.
- Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55:1209–1217.
- What You Should Know About Marijuana Concentrates. US Drug Enforcement Administration Web site.http://www.dea.gov/pr/multimedia-library/publications/marijuana-concentrates.pdf. Published December 2014. Accessed August 31, 2015.
- D'Souza DC, Perry E, MacDougall L, Ammerman Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558–1572.
- Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–1616.
- Paparelli A, Di Forti M, Morrison PD, Murray RM. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci. 2011;5:1–9.
- Stogner JM, Miller BL. The dabbing dilemma: a call for research on butane hash oil and other alternate forms of cannabis use. Subst Abus. 2015 Aug. [Epub ahead of print].
- Doan C. Officials warn of dangers associated with earwax marijuana. KCRA News Web site. http://www.kcra.com/news/officials-warn-of-dangers-associated-with-earwax-marijuana/23041300. Published November 18, 2013. Accessed August 31, 2015.
- Murphy CR, Martz G. Colorado marijuana businesses embrace new drug at center of DEA crackdown in California. ABC News Web site. http://abcnews.go.com/US/colo-marijuana-businesses-embrace-drug-center-dea-crackdown/story?id=22686105. Published February 26, 2014. Accessed August 31, 2015.
- Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatr. 2009;21:96–103.
- David AS, Prince M. Psychosis following head injury: a critical review. J Neurol Neurosurg Psychiatry 2005;76(Suppl 1):i53–i60.
- Fujii DC. Psychotic disorder due to traumatic brain injury: analysis of case studies in the literature. J Neuropsychiatry Clin Neurosci. 2012;24:278–289.
- Shenton ME, Hamoda HM, Schneiderman JS, et al. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. Brain Imaging Behav. 2012;6:137–192.
- Zuurman L, Passier PC, de Kam ML, Kleijn HJ, Cohen AF, Van Gerven JM. Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers. J Psychopharmacol. 2010;24:1689–1696.
- Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet. 2015;2:233–238.
- Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488–491.